Breast Cancer: Update Bulletin #3
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA approval of Lynparza (olaparib; AstraZeneca) for patients with metastatic BC with BRCA gene mutation; Pfizer’s talazoparib EMBRACA Phase III data in patients with advanced or metastatic BC; as well as Syndax Pharmaceuticals announcing a collaboration with Genentech for a Phase Ib/II trial evaluating the combination of entinostat with Tecentriq (atezolizumab) in patients with second-line HR+/HER2- metastatic BC.
How do KOLs view Lynparza’s approval?
What do KOLs consider Lynparza’s advantages/disadvantages?
According to KOLs, how will Lynparza be positioned?
How does talazoparib’s safety/efficacy compare to Lynparza?
Does talazoparib have any advantages over Lynparza?
What do KOLs think of combining entinostat with Tecentriq (atezolizumab)?
Which entinostat combination trial holds the most promise?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook